Bayer (BAYN) PT Set at €95.00 by Barclays

Barclays set a €95.00 ($117.28) price target on Bayer (FRA:BAYN) in a research report report published on Thursday. The firm currently has a sell rating on the healthcare company’s stock.

Other equities research analysts have also recently issued reports about the company. Baader Bank set a €140.00 ($172.84) target price on Bayer and gave the company a buy rating in a research note on Thursday, March 22nd. Sanford C. Bernstein set a €129.00 ($159.26) target price on Bayer and gave the company a buy rating in a research note on Wednesday, January 17th. UBS set a €125.00 ($154.32) target price on Bayer and gave the company a buy rating in a research note on Monday, February 5th. Deutsche Bank set a €120.00 ($148.15) target price on Bayer and gave the company a buy rating in a research note on Thursday, March 22nd. Finally, Independent Research set a €120.00 ($148.15) target price on Bayer and gave the company a neutral rating in a research note on Friday, January 12th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of €118.00 ($145.68).

How to Become a New Pot Stock Millionaire

BAYN stock opened at €98.65 ($121.79) on Thursday. Bayer has a 1 year low of €91.58 ($113.06) and a 1 year high of €123.82 ($152.86).

COPYRIGHT VIOLATION NOTICE: “Bayer (BAYN) PT Set at €95.00 by Barclays” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/04/16/bayer-bayn-pt-set-at-95-00-by-barclays.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply